Merkel cell carcinoma (MCC) is a rare skin cancer with a high risk of recurrence. MCPyV - Merkel cell polyomavirus - causes most cases, and in one large study, the virus was identified in more than 90 percent of MCC tumors examined. For patients with the virus, doctors check for MCPyV markers regularly after treatment.
These markers come in two forms: antibody titers (blood tests for proteins made against the virus) and circulating tumor DNA (ctDNA). Both tests are ordered about every three months under current guidelines. Both arrive as PDF lab reports. Without a system to connect them, no one compares this month's result to last month's automatically.
That gap is what Rucja Lab Intelligence closes.
Why Rising Titer Levels Matter
After treatment for MCPyV-positive MCC, antibody titers normally drop. A rising titer signals viral reactivation and likely cancer recurrence. A prospective validation study published in Cancer found that rising viral antibody titers predicted cancer recurrence with nearly 99 percent accuracy. This makes antibody titers one of the most reliable surveillance tools available for MCC follow-up.
The key word is rising. A single titer result only tells you whether it is high or low right now. The meaning comes from comparing the current value to the previous one. You need at least two results collected over time to see a trend.
A 2024 case series documented three patients with rising antibody levels whose cancers were not yet visible on imaging. Each patient needed multiple imaging tests to find the disease. The titer gave the earliest warning. But only if doctors were tracking it closely enough to act.
Testing Every Three Months Adds Up
Current guidelines recommend MCPyV antibody testing about every three months for patients under surveillance. A clinic managing 20 MCC patients generates roughly 80 titer results per year from this test alone - before imaging reports, blood counts, and other labs.
Each lab reports results differently. Some use dilution ratios like 1:400 or 1:1600. Others use signal-to-noise ratios or arbitrary units. Collection dates hide in report headers. Reference ranges vary between vendors. Without a system that standardizes these numbers, each comparison means manually finding and cross-checking old reports.
About half of MCC patients don't produce detectable antibodies against the virus. For these patients, ctDNA has become the main surveillance tool. A 2024 study found that ctDNA tests caught cancer recurrence and disease progression in both virus-positive and virus-negative patients. A 2025 analysis presented at the American Society of Clinical Oncology annual meeting compared ctDNA directly to MCPyV antibody testing and found that ctDNA caught recurrences in antibody-negative patients where antibody tests gave no signal. Tracking both test types at the same time makes the workflow harder unless both appear in one place.
How Lab Intelligence Extracts Results
Rucja Lab Intelligence uses AI to read lab reports - whether delivered as PDFs, electronic feeds, or scanned documents - and pull out the data that matters for MCC surveillance. Research on generative AI applied to unstructured clinical documents shows that extraction from lab reports can reach 99 percent accuracy. Lab Intelligence applies this approach to virus serology results.
For each MCPyV antibody result, the system finds and standardizes:
- The antibody titer value and its units
- The collection date - not the report date
- The test method used (ELISA, virus neutralization, or other)
- The reference range from that lab
- Whether the lab flagged it as positive, negative, or unclear
Different labs use different formats and units. These get stored as-is but mapped to a standard system. Results from two labs with different formats show up as one consistent timeline in the doctor's view instead of separate PDF files.
The same process works for ctDNA results: fragment counts and other numbers are captured, standardized, and added to the patient's lab history. The doctor opens one view and sees both types of test together.
From Numbers to a Trend the Doctor Can Use
Pulling out the data is just the start. The real value comes from showing the trend.
Once Lab Intelligence has processed two or more MCPyV antibody results for a patient, the doctor portal displays them as a timeline by collection date. The change between the two most recent tests shows as a number next to the graph. When that change goes up past a set threshold - meaning the titer is rising instead of falling or staying flat - Lab Intelligence alerts the care team in the portal.
This matches the evidence: the direction the titer moves, not the number itself at any one moment, tells you whether cancer is returning. A graph makes that direction visible in seconds. A stack of PDFs does not.
For antibody-negative patients, the same display works for ctDNA. The doctor doesn't have to switch between programs or manually gather reports from two different labs. Both tests appear in one portal view at the same visit.
The extraction and display method used here follows the same principles applied to other viral markers. For a similar example, see HPV viral load monitoring gaps in anal cancer surveillance. For a broader explanation of how AI extraction changes clinical routines, see how AI lab extraction changes clinical routine.
Connecting Results to Scheduling and Compliance
Lab Intelligence is part of the Rucja platform. When a rising MCPyV alert appears, it shows in the same view the doctor is already using. The care team can request imaging from that alert without leaving the patient record. The signal and the response stay in one place.
For practices with multiple oncologists - such as academic centers with surgical oncology, radiation oncology, and medical oncology teams - Lab Intelligence logs every extraction event. Every result read, every alert generated, and every number captured gets timestamped. This enables quality review and compliance documentation without extra work from staff.
This tracking approach works across rare cancer surveillance. The same tools that monitor MCPyV titers for MCC teams also handle other hard-to-track markers in oncology, like mesothelin velocity tracking in pleural mesothelioma monitoring.
MCC is too rare to miss an early warning. Three-month testing creates modest data, but each result matters. Lab Intelligence makes sure that trend is visible - organized, graphed, and ready to act on - before the next visit, not hidden in old reports.
Demos take 30 minutes. We will walk you through the Lab Intelligence workflow using a real MCC surveillance case and show how extracted results appear as graphs in the doctor portal. Book a demo with the Rucja team.